Objectives To evaluate whether type 2 diabetes mellitus (T2DM) presence and severity are associated with differences in global and domain-specific cognitive function among US adults, using ...
A DGIST research team led by Prof. Yoo Wookyung (Department of Brain Sciences) and Prof. Kim Jin Hae (Department of New Biology) developed an innovative analytical technology in collaboration with a ...
The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD).
Sleeping for 7 hours and 18 minutes every night may be the sweet spot for warding off the risk of insulin resistance—the ...
Researchers are developing a two-part therapy for type 1 diabetes: lab-made insulin-producing cells paired with ...
Insulet Stock: why GLP-1 fears are overblown, with growth driven by Europe/MENA expansion. Read here for a detailed analysis on PODD stock.
StockStory.org on MSN
PODD Q4 deep dive: Type 2 diabetes expansion and innovation drive outperformance
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2025 results , with sales up 31.2% year on year to $783.8 million. The company expects next quarter’s revenue to be around $716 ...
WAN CHAI, WAN CHAI, HONG KONG, January 23, 2026 /EINPresswire.com/ — Even with the advancement of Automated Insulin Delivery (AID) technologies, diabetes management ...
The AACE consensus statement emphasizes improvement of overall health in addition to weight reduction among adults with obesity and adiposity-based chronic disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results